Cite

HARVARD Citation

    Pirosa, M. et al. (n.d.). PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38). Hematological oncology. p. n/a. [Online]. 
  
Back to record